New developments in the management of congenital Factor XIII deficiency
Zehra Fadoo,1 Quratulain Merchant,2,* Karim Abdur Rehman2,* 1Department of Pediatrics and Child Health, 2Medical College, Aga Khan University, Karachi, Pakistan *These authors contributed equally to this workAbstract: Congenital Factor XIII (FXIII) deficiency is a rare, inherited, autosomal recessiv...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-05-01
|
| Series: | Journal of Blood Medicine |
| Online Access: | http://www.dovepress.com/new-developments-in-the-management-of-congenital-factor-xiii-deficienc-a13170 |
| _version_ | 1818499705443713024 |
|---|---|
| author | Fadoo Z Merchant Q Rehman KA |
| author_facet | Fadoo Z Merchant Q Rehman KA |
| author_sort | Fadoo Z |
| collection | DOAJ |
| description | Zehra Fadoo,1 Quratulain Merchant,2,* Karim Abdur Rehman2,* 1Department of Pediatrics and Child Health, 2Medical College, Aga Khan University, Karachi, Pakistan *These authors contributed equally to this workAbstract: Congenital Factor XIII (FXIII) deficiency is a rare, inherited, autosomal recessive coagulation disorder. Most mutations of this condition are found in the A-subunit with almost half these being missense mutations. Globally, approximately one in three million people suffer from this deficiency. Factor XIII deficiency is associated with severe life threatening bleeding, intracranial hemorrhage, impaired wound healing, and recurrent pregnancy losses. FXIII is known to have a potential role in mediating inflammatory processes, insulin resistance, bone metabolism, neoplasia, and angiogenesis. The algorithm provided for FXIII diagnosis and classification will enable prompt identification and early intervention for controlling potential life threatening complications. Prophylactic replacement therapy using blood products containing FXIII such as fresh frozen plasma, cryoprecipitate, or using FXIII concentrate remains the mainstay for the management of FXIII deficiency. In most parts of the world, cryoprecipitate and plasma transfusions are the only treatments available. Management developments have revealed the effectiveness and safety of recombinant FXIII concentrate for prophylaxis and treatment. The aim of this review is to provide an overview of advancements made in the management of FXIII deficiency from the time it was first detected, highlighting novel developments made in recent years. Greater research is warranted in identifying novel approaches to manage FXIII deficiency in light of its underlying pathophysiology.Keywords: Factor XIII, Factor XIII deficiency, treatment, diagnosis, inherited coagulative disorders |
| first_indexed | 2024-12-10T20:33:04Z |
| format | Article |
| id | doaj.art-fe77ffab6f604967917a59c5cae90a23 |
| institution | Directory Open Access Journal |
| issn | 1179-2736 |
| language | English |
| last_indexed | 2024-12-10T20:33:04Z |
| publishDate | 2013-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Blood Medicine |
| spelling | doaj.art-fe77ffab6f604967917a59c5cae90a232022-12-22T01:34:38ZengDove Medical PressJournal of Blood Medicine1179-27362013-05-012013default6573New developments in the management of congenital Factor XIII deficiencyFadoo ZMerchant QRehman KAZehra Fadoo,1 Quratulain Merchant,2,* Karim Abdur Rehman2,* 1Department of Pediatrics and Child Health, 2Medical College, Aga Khan University, Karachi, Pakistan *These authors contributed equally to this workAbstract: Congenital Factor XIII (FXIII) deficiency is a rare, inherited, autosomal recessive coagulation disorder. Most mutations of this condition are found in the A-subunit with almost half these being missense mutations. Globally, approximately one in three million people suffer from this deficiency. Factor XIII deficiency is associated with severe life threatening bleeding, intracranial hemorrhage, impaired wound healing, and recurrent pregnancy losses. FXIII is known to have a potential role in mediating inflammatory processes, insulin resistance, bone metabolism, neoplasia, and angiogenesis. The algorithm provided for FXIII diagnosis and classification will enable prompt identification and early intervention for controlling potential life threatening complications. Prophylactic replacement therapy using blood products containing FXIII such as fresh frozen plasma, cryoprecipitate, or using FXIII concentrate remains the mainstay for the management of FXIII deficiency. In most parts of the world, cryoprecipitate and plasma transfusions are the only treatments available. Management developments have revealed the effectiveness and safety of recombinant FXIII concentrate for prophylaxis and treatment. The aim of this review is to provide an overview of advancements made in the management of FXIII deficiency from the time it was first detected, highlighting novel developments made in recent years. Greater research is warranted in identifying novel approaches to manage FXIII deficiency in light of its underlying pathophysiology.Keywords: Factor XIII, Factor XIII deficiency, treatment, diagnosis, inherited coagulative disordershttp://www.dovepress.com/new-developments-in-the-management-of-congenital-factor-xiii-deficienc-a13170 |
| spellingShingle | Fadoo Z Merchant Q Rehman KA New developments in the management of congenital Factor XIII deficiency Journal of Blood Medicine |
| title | New developments in the management of congenital Factor XIII deficiency |
| title_full | New developments in the management of congenital Factor XIII deficiency |
| title_fullStr | New developments in the management of congenital Factor XIII deficiency |
| title_full_unstemmed | New developments in the management of congenital Factor XIII deficiency |
| title_short | New developments in the management of congenital Factor XIII deficiency |
| title_sort | new developments in the management of congenital factor xiii deficiency |
| url | http://www.dovepress.com/new-developments-in-the-management-of-congenital-factor-xiii-deficienc-a13170 |
| work_keys_str_mv | AT fadooz newdevelopmentsinthemanagementofcongenitalfactorxiiideficiency AT merchantq newdevelopmentsinthemanagementofcongenitalfactorxiiideficiency AT rehmanka newdevelopmentsinthemanagementofcongenitalfactorxiiideficiency |